Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced
4/26/2017 Tesaro (TSRO) is using some funky math and PR razzle dazzle to make the price of its newly approved PARP inhibitor Zejula look cheaper than it really is for treating ovarian cancer. In a statement Wednesday tied to the drug's commercial launch, Tesaro ...
Unexpected Benefit Links Hypertension to Better Ovarian Cancer Outcomes
4/26/2017 Using pooled data from 15 studies that were part of the Ovarian Cancer Association Consortium, Kirsten Moysich, PhD, MS, and Albina Minlikeeva, PhD, MPH, of the Roswell Park Cancer Institute in Buffalo, retroactively examined the associations between ...
Mateon announces positive topline data in ovarian cancer
4/26/2017 Interim results from Mateon Therapeutics' Phase 2/3 study in patients with platinum resistant ovarian cancer (prOC) show cautious optimism for both the safety and efficacy of its vascular disrupting agent, CA4P (fosbretabulin), albeit in the small ...
Dr. Barber on Chemotherapy Versus Surgery for Ovarian Cancer
4/26/2017 Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy versus surgery for patients with ovarian cancer. Physicians tend to think of ...
Judy's Mission to Hold Annual Luncheon Benefitting Ovarian Cancer Awareness
4/26/2017 HOUSTON, April 24, 2017 /PRNewswire/ -- Judy's Mission Ovarian Cancer Foundation will hold its annual Mission Possible Luncheon, titled "Laughter is the Best Medicine," on May 12, 2017 at the Junior League of Houston.
Personalized Screening Improves Early Detection of Deadly Ovarian Cancer
4/26/2017 Many cancers announce their presence with recognizable symptoms, but ovarian cancer is so evasive that it rarely gives clues until it's too late.
Ovarian cancer survivor prepares for Sandy Sprint, with help from new drug
4/26/2017 The FDA has just OK'd the third in a new class of drugs giving longer life, and hope to ovarian cancer patients. Zejula joins Rubraca and Lynparza, which are already on the market.
High Blood Pressure: A Silver Lining for Ovarian Cancer Patients?
4/26/2017 However, high blood pressure was linked to a 46 percent lower risk of progression for women with endometrioid ovarian cancer. This type of cancer is a subtype of epithelial ovarian cancer. Endometrioid ovarian cancer usually has better outcomes, the ...
Ovarian Cancer Market Will “More than Quadruple” by 2025
4/26/2017 Ovarian Cancer Market Will “More than Quadruple” by 2025. Apr 25, 2017. By Pharmaceutical Executive Editors. The ovarian cancer arena across the seven major markets—US, France, Germany, Italy, Spain, the UK, and Japan—will increase from around ...
Health Matters: Screening for Ovarian Cancer
4/26/2017 It's one of the most common cancer deaths for women, but doctors say there's no way to screen for ovarian cancer. Dr.